OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
On June 28, 2019, David M. Rubin, Ph.D., a director of OpGen, Inc. (the Company”) since 2015 submitted his resignation as a director effective June 30, 2019. In addition, Timothy J.R. Harris, Ph.D., D.Sc., a director of the Company since 2015, who had previously notified the Chairman of the Board of Directors of the Company that, for personal reasons, he would not seek to be re-nominated for election at the next annual meeting of the Company, notified the Company that his service would end on June 30, 2019. There was no disagreement between either of Dr. Rubin or Dr. Harris and the Company leading to the decisions to resign.
Dr. Rubin had served on the Audit Committee of the Board. The Board re-appointed Tina S. Nova, Ph.D. to the Audit Committee effective July 1, 2019. The Board determined that Dr. Nova is independent and has the necessary skills and qualifications to serve on the Audit Committee.
About OpGen, Inc. (NASDAQ:OPGN)
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.
